v2.3.0.15
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
3 Months Ended6 Months Ended12 Months Ended
Jun. 30, 2011
Jun. 30, 2010
Jun. 30, 2011
Jun. 30, 2010
Dec. 31, 2010
Dec. 31, 2009
Product sales, net$ 222,129$ 137,528$ 323,376$ 313,151$ 862,369$ 734,495
Cost of goods sold(142,573)(95,045)(235,197)(176,812)(497,954)(368,524)
Inventory adjustment (63,194) (63,194)(256,948)(58,773)
Gross profit79,556(20,711)88,17973,145107,467307,198
Patent impairment charge    (1,749,664) 
Operating, sales and administrative expenses(2,598,463)(717,930)(3,169,577)(1,319,675)(3,294,930)(2,094,303)
Net loss from operations(2,518,907)(738,641)(3,081,398)(1,246,530)(4,937,127)(1,787,105)
Other income (expense):      
Interest expense(551,778)(416,439)(1,235,342)(1,403,980)(2,195,151)(656,450)
Change in fair value of derivative instruments(711,000)831,044(818,545)862,9581,709,029(13,600)
(Gain) loss on settlement of debt (478,262) (478,262)(478,262)105,684
Beneficial conversion features    (606,400) 
Charge resulting from triggered anti-dilution provisions within financial instruments(187,416) (854,560) (482,866) 
Other expenses(40,596)(12,000)(152,899)(27,960)(49,990)(88,380)
Total other income (expense)(1,490,790)(75,657)(3,061,346)(1,047,244)(2,103,640)(652,746)
Net loss(4,009,697)(814,298)(6,142,744)(2,293,774)(7,040,767)(2,439,851)
Deemed dividend on Series B Preferred Stock     (985,000)
Net loss applicable to common shareholders    $ (7,040,767)$ (3,424,851)
Weighted average number of common shares outstanding, basic and diluted13,245,9659,477,80512,200,4529,511,6581,970,541,9611,208,492,443
Basic and diluted net loss per common share$ (0.30)$ (0.09)$ (0.50)$ (0.24)$ 0.00$ 0.00
pro forma
      
Other income (expense):      
Weighted average number of common shares outstanding, basic and diluted    9,852,7106,042,462
Basic and diluted net loss per common share    $ (0.71)$ (0.57)